Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists’ offices
- 1 January 2003
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 19 (4) , 330-335
Abstract
SUMMARYPurpose: To analyse a response to the therapy switch from the concomitant application of β-blocker and topical carbonic anhydrase inhibitor to the fixed combination of timolol and dorzolamide (Cosopt) in glaucoma/ocular hypertensive patients under everyday, office-practice conditions. * Cosopt is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USAPatients and methods: The data source was a survey among practising ophthalmologists in Switzerland assessing their experience with glaucoma patients/ocular hypertensives put for the first time on the fixed combination of timolol and dorzolamide. A total of 98 patients underwent the therapy switch in at least one eye. The intraocular pressure (IOP) change between the baseline visit before switch to the timolol-dorzolamide fixed combination occurred, and the first follow-up control after the switch, served as an indicator of compliance.Results: The IOP decreased on average from 19.43 ± 5.64 mmHg to 17.97 ± 3.58 mmHg (p < 0.01). The time...Keywords
This publication has 4 references indexed in Scilit:
- Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence studyBritish Journal of Ophthalmology, 1998
- The efficacy and safety of the Dorzolamide—timolol combination versus the concomitant administration of its components11Ms. Strohmaier and Drs. Snyder and Adamsons are employees of Merck & Co., Inc, the manufacturer of the dorzolamide-timolol combination. Dr. DuBiner has no proprietary interest in the dorzolamide-timolol combination or Merck.Ophthalmology, 1998
- A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide11Ms. Boyle, Dr. Ghosh, and Dr. Adamsons were employees of Merck & Co., Inc, the manufacturer of timolol and dorzolamide, at the time this study was conducted. COSOPT and TRUSOPT are trademark products of Merck & Co., Inc, Whitehouse Station, New Jersey. The other authors have no proprietary interest in timolol, dorzolamide, or Merck.Ophthalmology, 1998
- Facilitating patient compliance in glaucoma therapySurvey of Ophthalmology, 1983